Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1648083 | 0.89 | ALOX5 (0.38) | MTNR1AMTNR1BALDH1A1LMNAL3MBTL1 | |
| SCHEMBL1648221 | 0.88 | ALOX5 (0.43) | ALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL1648989 | 0.88 | L3MBTL1 (0.40) | ALDH1A1LMNAL3MBTL1MAPTKMT2A | |
| SCHEMBL1648194 | 0.87 | L3MBTL1 (0.46) | ALDH1A1LMNAL3MBTL1MAPTKMT2A | |
| SCHEMBL1650025 | 0.80 | ALOX5 (0.39) | ALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL18801445 | 0.79 | MTNR1A (0.40) | MTNR1AMTNR1BALDH1A1LMNAL3MBTL1 | |
| SCHEMBL1648293 | 0.79 | KMT2A (0.39) | ALDH1A1LMNAMAPTHSD17B10KMT2A | |
| SCHEMBL1648422 | 0.78 | ALOX5 (0.52) | ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL18801137 | 0.77 | KMT2A (0.43) | ALDH1A1LMNAL3MBTL1MAPTHSD17B10 | |
| SCHEMBL1648273 | 0.77 | CA12 (0.41) | LMNAMAPTHSD17B10KMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, STS | MTNR1A 1752/4885MTNR1B 916/4885ALDH1A1 360/4885 |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | METAP2, DNPEP, STS | MTNR1A 1752/4885MTNR1B 916/4885ALDH1A1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.